Abstract 1857
Background
MET gene amplification/mutation is implicated in oncogenesis of many tumor types. Sym015 is a recombinant antibody (Ab) mixture containing 2 humanized Abs binding non-overlapping epitopes on MET which has superior preclinical activity compared to other MET Abs. Here we present interim results from the First in Human study of Sym015.
Methods
In part 1 dose escalation, Sym015 was evaluated on every 2-week (q2w) schedule at 6/12/18/24 mg/kg doses in late line advanced solid tumor patients (pts). Based on PK/PD assessment, 18 mg/kg loading dose followed by 12 mg/kg q2w was selected as RP2D. The on-going Part 2 Dose expansion enrolls pts with MET amplification (METAmp >5 MET copies by Next Generation Sequencing (NGS) or FISH MET/CEP7 ratio >2.2 updated to ≥ 3.0) and/or MET exon 14 deletion (METEx14Δ) positive tumors. Central FISH confirmation of tumor MET status and longitudinal circulating tumor (ct)DNA profiling is performed.
Results
By April 2019, 51 pts (median age 61 yrs) have been treated, 12 pts in Part 1 and 39 pts in Part 2, the majority are non small cell lung cancer (NSCLC; 14 pts; 6 METAmp,7 METEx14Δ, 1 both) and gastric cancer (GC; 12 METAmp pts). Treatment-related adverse events (TRAE) occurred overall in 41,2%; TRAE ≥ gr3 in 9,8% (edema, colitis, septic shock, hypoalbuminemia, hypophosphatemia, increased amylase). No pts discontinued or died due to TRAE. The most common TRAE of ≥ 5% were fatigue 15.7%, peripheral edema 7,8%, nausea, decreased appetite, pruritus and abdominal pain reported by 5.9% of pts each. The table shows preliminary efficacy in NSCLC patients. Sym015 PK was slightly non-linear, with a dose-dependent t½ of 7-10 days for the first dose. 83% METAmp concordance (10/12 samples) between tumor and blood was observed.Table:
1490PD
NSCLC Pt | MET Status (Local Assessment) | Best Response (Best % Change From Baseline) | Previous MET TKI therapy | Duration of Response (weeks) |
---|---|---|---|---|
1 | METAmp NGS 6.8 Copies | PR (-53%) | No | 80 |
2 | METAmp NGS >5 Copies | SD (-29%) | No | 9, Ongoing |
3 | METAmp NGS >5 Copies | SD (+3%) | No | 9, Ongoing |
4 | METEx14Δ | SD (-28%) | No | 7, Ongoing |
5 | METAmp FISH MET/ CEP7:4.9 | SD (+6%) | No | 11 |
6 | METEx14Δ | SD (-4%) | Yes | 8 |
7 | METEx14Δ | SD (-21%) | Yes | 15 |
8 | METEx14Δ | SD (-20%) | Yes | 8 |
9 | METAmp SISH MET/ CEP7: 15.2 | Pending | No | Ongoing |
10 | METEx14Δ | Pending | Yes | Ongoing |
11 | METEx14Δ + METAmp | Pending | Pending | Ongoing |
12 | METEx14Δ | Pending | No | Ongoing |
13 | METEx14Δ | Pending | No | Ongoing |
14 | METEx14Δ | Not Evaluable | Yes | Not Evaluable |
Conclusions
Sym015 was well tolerated with early evidence of antitumor activity. Predictive biomarker analysis is underway. The study continues to enroll NSCLC patients with METAmp and/or METEx14Δ. MET screening in blood seems feasible and may be included in future trials.
Clinical trial identification
NCT02648724.
Editorial acknowledgement
Legal entity responsible for the study
Symphogen A/S.
Funding
Symphogen A/S.
Disclosure
D.R. Camidge: Advisory / Consultancy: 2019: Takeda, CBT Pharmaceuticals, Daiichi-Sankyo (ILD adjudication committee), G1 Therapeutics (DSMB), Bio-Thera (DSMB), Blueprint; Advisory / Consultancy: 2018: AstraZeneca, Takeda, Arrys/Kyn, Regeneron, Hengrui, G1 Therapeutics (DSMB), Daiichi Sankyo (ILD adjudication committee), Hansoh (SRC), Bio-Thera (DSMB), Ribon, BMS, Blueprint, Roche/Genentech, Inivata; Advisory / Consultancy: 2017: Genoptix, G1 Therapeutics (DSMB), Mersana Therapeutics, Roche/Genentech, Takeda, Ignyta, Daiichi Sankyo (ILD adjudication committee), Hansoh SRC, Bio-Thera DSMB, Lycera, Revolution Med; Research grant / Funding (self), Research grant / Funding (institution): 2017: Takeda Investigator-initiated Trial; Research grant / Funding (self), Research grant / Funding (institution), Company Sponsored Trials at Institution: 2018/9: AbbVie, AstraZeneca, BMS, Hansoh, Lycera, MedImmune, Merck, Pfizer, Phosplatin, Roche/Genentech, Seattle Genetics, Symphogen, Takeda. F. Janku: Research grant / Funding (self): Novartis, Genentech, BioMed Valley Discoveries, Astellas, Agios, Plexxikon, Deciphera, Piqur, Symphogen, Bristol-Myers Squibb, Asana, Upsher-Smith Laboratories; Advisory / Consultancy: Guardant Health, IFM Therapeutics, Synlogic, Deciphera; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Trovagene; Advisory / Consultancy: Immunomet. D.V. Catenacci: Honoraria (self), Advisory / Consultancy: Merck, BMS, Lilly, Astellas, Gritstone, Taiho, Five Prime, Genentech Roche, Foundation Medicine, Guardant Health, Tempus. H.C. Chung: Honoraria (self): Merck-Serono, Lilly, Foundation Medicine; Advisory / Consultancy: Taiho, Celltrion, MSD, Lilly,Quintiles, BMS, Merck-Serono; Research grant / Funding (institution): Lilly, GSK, MSD, Merck-Serono, BMS-ONO, Taiho. A. Dowlati: Advisory / Consultancy: Seattle genetics, Takeda, AbbVie; Research grant / Funding (institution): Takeda, Taiho, Roche, EMD Serono, Bayer, Tesaro, Regeneron, Amgen, Mirati, BMS. K.S. Rohrberg: Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Research grant / Funding (institution): Loxo Oncology, Orion Pharma, Pfizer, PUMA, Cantargia, Genmab, Novartis, Incyte, Bayer, AstraZeneca, Alligator, Merck, BMS; Travel / Accommodation / Expenses: Sanofi; Research grant / Funding (institution): Symphogen. T.T. Poulsen: Full / Part-time employment: Symphogen A/S. H. Rudbæk: Full / Part-time employment: Symphogen A/S. L. Alifrangis: Full / Part-time employment: Symphogen A/S. R.P. Dalal: Full / Part-time employment: Symphogen A/S. All other authors have declared no conflicts of interest.
Resources from the same session
4597 - Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407
Presenter: Steven Powell
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
3850 - Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC
Presenter: Tony S.K. Mok
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
6131 - Safety and efficacy of WX-0593 in ALK-positive or ROS1-positive non-small cell lung cancer
Presenter: Yuan-Kai Shi
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
1906 - Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients
Presenter: Steffie Groenland
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
2577 - Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting
Presenter: D. Ross Camidge
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
4178 - Entrectinib in Locally Advanced/Metastatic ROS1 and NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Updated Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo Guglielmo De Braud
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
4899 - Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: results of the prospective PFROST trial
Presenter: Lorenza Landi
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
4134 - Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407
Presenter: Luis Paz-Ares
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
Slides
2239 - Final efficacy results from B-F1RST, a prospective Phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
Presenter: Mark Socinski
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
2584 - Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Andrea Ardizzoni
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract